ライフサイエンスコーパス: complement receptor

1 the presence of blocking Abs to FcgammaR and complement receptor.

2 fects B lymphocytes through their CD21 (CR2) complement receptor.

3 be eliminated by microglial cells expressing complement receptors.

4 sulting in vesicle recognition by macrophage complement receptors.

5 Ig receptors (FcRgammaI and FcgammaRIII) or complement receptors.

6 sonization and binding of these complexes to complement receptors.

7 , FcgammaRIV, the inhibitory FcgammaRIIB and complement receptors.

8 psonized particles become immune adherent to complement receptor 1 (CR1 or CD35) on human erythrocyte

9 ly lack the third component of complement or complement receptor 1 (CR1) and CR2 developed increased

10 levels of E-bound Abs, reduced E-associated complement receptor 1 (CR1) and decay-accelerating facto

11 Complement receptor 1 (CR1) expressed on the surface of

12 c analyses to investigate the involvement of complement receptor 1 (CR1) in P. vivax invasion.

13 Clustering of Complement Receptor 1 (CR1) in the erythrocyte membrane

14 Complement receptor 1 (CR1) is an Alzheimer's disease (A

15 Complement receptor 1 (CR1) on human erythrocytes (Es) a

16 ng protein-like homologue 4 (PfRh4) binds to complement receptor 1 (CR1) to mediate entry of malaria

17 veral receptors, including sialic acid (SA), complement receptor 1 (CR1), and basigin.

18 omplement-regulatory proteins, in particular complement receptor 1 (CR1), are important in the pathog

19 geted Cr2(-/-) mice, which lack both CR2 and complement receptor 1 (CR1), have demonstrated contradic

20 iated with unusual deposits located near the complement receptor 1 (CR1)-expressing podocytes.

21 to phagocytes by human erythrocytes bearing complement receptor 1 (CR1).

22 immune complexes via erythrocytes expressing complement receptor 1 (CR1).

23 native LDL and acetylated LDL (acLDL) to the complement receptor 1 (CR1).

24 D55), membrane cofactor protein (MCP, CD46), complement receptor 1 (CR1, CD35) and viral molecules su

25 r primates are unique among mammals in using complement receptor 1 (CR1, CD35) on red blood cells (RB

26 During this process, RBCs use complement receptor 1 (CR1, CD35) to bind circulating co

27 ce or absence of blocking Abs to CD23, CD32, complement receptor 1 (CR1, CD35), and/or CR2 (CD21) was

28 The primary identified function of complement receptor 1 (CR1/CD35) on primate erythrocytes

29 , membrane cofactor protein (MCP; CD46), and complement receptor 1 (CR1; CD35).

30 Human complement receptor 1 (HuCR1) is a pivotal regulator of

31 ned approach was augmented by adding soluble complement receptor 1 (sCR1) to the perfusate in one fur

32 D47-blocking antibody (alphaCD47Ab), soluble complement receptor 1 (sCR1), and recombinant thrombomod

33 tabilized C3bBb and perturbed C3b binding to complement receptor 1 but did not perturb binding to fac

34 the recognition of deposited C3 fragments by complement receptor 1 even when the absolute number of C

35 -tetanus toxoid antibody levels, erythrocyte complement receptor 1 expression, and lymphocyte prolife

36 ynonymous SNP, rs6691117 (Val-->IIe), in the complement receptor 1 gene (CR1) was associated with ESR

37 s functions analogously to human erythrocyte complement receptor 1 in its role to traffic immune comp

38 up had a progressive increase in erythrocyte complement receptor 1 levels compared with baseline (P =

39 Complement receptor 1 levels on erythrocytes (ECR1) toge

40 o evaluate new therapeutic targets employing complement receptor 1 peptide homologues and the antimac

41 the functional analogue to human erythrocyte complement receptor 1 with a role that is distinct from

42 negative complement regulators Factor H and complement receptor 1 with C3b.

43 lowed us to discover that expression of CR1 (complement receptor 1), an AD susceptibility gene involv

44 factors, such as decay accelerating factor, complement receptor 1, and factor H, which directly inte

45 tors, such as factor H, C4b-binding protein, complement receptor 1, and membrane cofactor protein.

46 on host cells by the complement system, and complement receptor 1-like protein y (CRRY) is an import

47 Complement receptor 1-related gene/protein y (Crry) and

48 Decay-accelerating factor (DAF) and complement receptor 1-related gene/protein y (Crry) are

49 In a model system in which RBCs deficient in complement receptor 1-related gene/protein y (Crry) are

50 of either decay-accelerating factor (DAF) or complement receptor 1-related gene/protein y (Crry) on m

51 lement inhibition with complement receptor 2-complement receptor 1-related protein y (CR2-Crry, an in

52 This phenotype, which shared features with complement receptor 1-related protein Y (Crry) depletion

53 We found that loss of polarity of complement receptor 1-related protein y (Crry) in the tu

54 ow that deleting the C3 convertase regulator complement receptor 1-related protein y (Crry) induces m

55 IL-17 differentially suppressed complement receptor 1-related protein y expression in ai

56 lement-regulatory protein (CRP) (CD55, CD46, complement receptor 1-related protein y/CD46) expression

57 se Cfh as the functional surrogate for human complement receptor 1.

58 C3 fragments on the organism from binding to complement receptor 1.

59 eraction of C3b with Factor B, Factor H, and complement receptor 1.

60 tibodies to block P. falciparum invasion via complement receptor 1.

61 mediated by NTS-DBL1alpha interactions with complement receptor 1.

62 g WNV infection in complement (C) 3(-/-) and complement receptor 1/2(-/-) mice.

63 complexes (ICs) from noncognate B cells via complement receptors 1 and 2 (CD35 and CD21, respectivel

64 d alone, an effect requiring the presence of complement receptors 1 and 2 (CR1/2).

65 Cr2, which encodes complement receptors 1 and 2 (CR1/CR2; CD35/CD21), is a

66 lly depleted of complement, or deficient for complement receptors 1 and 2, were also susceptible to s

67 that FPR activation leads to upregulation of complement receptors 1 and 3 as well as FCgamma receptor

68 on with (99m)Technecium-labelled recombinant complement receptor 2 ((99m)Tc-rCR2), which specifically

69 ntibody assay, we found that viral gp350 and complement receptor 2 (CD21) are required for CD3(+) T-c

70 ctivation through coengagment of the BCR and complement receptor 2 (CD21).

71 rough the interaction between complement and complement receptor 2 (CR2 [CD21]).

72 of complement component C3d with B or T cell complement receptor 2 (CR2 or CD21) is a link between in

73 inant mouse protein composed of domains from complement receptor 2 (CR2) and FH (CR2-FH) in two model

74 consisting of the iC3b/C3d-binding region of complement receptor 2 (CR2) and the inhibitory domain of

75 mia-reperfusion (IR)-induced damage requires complement receptor 2 (CR2) for generation of the approp

76 receptor(s), we found that App1 does bind to complement receptor 2 (CR2) in a dose-dependent manner.

77 eraction between complement fragment C3d and complement receptor 2 (CR2) is a key aspect of complemen

78 ntains the AP-inhibitory domain, linked to a complement receptor 2 (CR2) targeting fragment that bind

79 nking an iC3b/C3dg-binding fragment of mouse complement receptor 2 (CR2) to a mouse complement-inhibi

80 cantly enhanced when linked to a fragment of complement receptor 2 (CR2), a receptor that targets C3

81 We discovered that complement receptor 2 (CR2), classically known as a core

82 A positional candidate gene at 1q32.2, complement receptor 2 (CR2), is also a candidate in the

83 le of inhibiting the interaction of C3d with complement receptor 2 (CR2), which plays an important ro

84 The interaction of complement receptor 2 (CR2)--which is present on B cells

85 , targeted complement inhibition with either complement receptor 2 (CR2)-Crry (blocks all pathways at

86 Complement receptor 2 (CR2)-Crry inhibits complement act

87 We investigated the use of complement receptor 2 (CR2)-Crry, a complement inhibitor

88 Complement receptor 2 (CR2, CD21) is a cell membrane pro

89 Complement receptor 2 (CR2/CD21) is part of the B-cell c

90 nt that can facilitate the coligation of the complement receptor 2 (CR2/CD21) with the BCR via C3dg/A

91 that mediates attachment to B cells through complement receptor 2 (CR2/CD21).

92 Complement receptor 2 (CR2; CD21) is a membrane-bound re

93 The C3-binding domain of human complement receptor 2 (CR2; CD21) was linked to the comp

94 ect of a recombinant AP inhibitor containing complement receptor 2 and factor H (CR2-fH) on CAIA in m

95 ed in the lung and occurred independently of complement receptor 2 and Fcgamma receptors, but was dep

96 that contains the iC3b/C3d binding region of complement receptor 2 linked to the inhibitory region of

97 GT-/- mice were crossed with complement receptor 2 loci knockout mice to generate dou

98 via complement protein 3d and antigen to the complement receptor 2 signaling complex.

99 potential HIV-binding molecules FcRgammaIII, complement receptor 2, and various complement components

100 3) deficiency and complement inhibition with complement receptor 2-complement receptor 1-related prot

101 Complement receptor 2-deficient (Cr2(-/-)) mice are resi

102 Complement receptor 2-negative (CR2/CD21(-)) B cells hav

103 21/35(-/-) mice, deficient in CD21 and CD35 (complement receptors 2 and 1, respectively), were infect

104 omplement component C3 (C3d) and the modular complement receptor-2 (CR2) is important for cross-linki

105 rHDL attenuated the amount of CC-induced complement receptor 3 (CD11b/CD18) expression on monocyt

106 Ab blockade of the integrin complement receptor 3 (CD11b/CD18) significantly inhibit

107 e is dependent on beta-glucan recognition by complement receptor 3 (CD11b/CD18), but not Dectin-1, or

108 ement activation resulted in upregulation of complement receptor 3 (CD11b/CD18), leading to phagocyto

109 dition to the I-domain, the beta(2) integrin complement receptor 3 (CR3) (CD11b/CD18) contains a lect

110 gested that beta2 integrin receptors such as complement receptor 3 (CR3) and 4 (CR4) may act as novel

111 Complement receptor 3 (CR3) and CD36 have been suggested

112 Interestingly, we also found that both complement receptor 3 (CR3) and dectin-1 play a crucial

113 ggestive of binding to the lectin domains of complement receptor 3 (CR3) and dectin-1.

114 A role for both complement receptor 3 (CR3) and Fcgamma receptors in upt

115 Among AM receptors, complement receptor 3 (CR3) and FcRgamma are the most co

116 ized C albicans was found to be dependent on complement receptor 3 (CR3) and the signaling proteins p

117 Complement Receptor 3 (CR3) and Toll-like Receptor 2 (TL

118 s also unaffected in mice deficient in C3 or complement receptor 3 (CR3) but was almost completely ab

119 ich was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells.

120 Neisseria gonorrhoeae can engage human complement receptor 3 (CR3) directly or through surface-

121 Small molecule antagonists to complement receptor 3 (CR3) have been widely sought, but

122 ls (HPCs) and the role of complement (C) and complement receptor 3 (CR3) in BM injury/repair.

123 we uncovered a novel role for the microglial complement receptor 3 (CR3) in the regulation of soluble

124 with the complement C3dg, can interact with complement receptor 3 (CR3) on activated monocytes, thus

125 ion resulted in reduced bacterial binding to complement receptor 3 (CR3) on the surface of murine mac

126 ial for beta2-induced accumulation of Rho at complement receptor 3 (CR3) phagosomes.

127 Complement receptor 3 (CR3), a genetic variant of which

128 ecifically iC3b production and engagement of complement receptor 3 (CR3), had a significant impact on

129 ophages isolated from mannose receptor (MR), complement receptor 3 (CR3), MyD88, Toll-like receptor 4

130 ional and oligomeric states: the BCR and the complement receptor 3 (CR3), on murine splenocytes, puri

131 identified complement receptor CRIg, but not complement receptor 3 (CR3), rescued DAF/Crry-deficient

132 These receptors include complement receptor 3 (CR3), used by promastigotes, and

133 ially binds an inactive form of the integrin complement receptor 3 (CR3), using a site outside of its

134 male mice following irradiation is microglia complement receptor 3 (CR3)-dependent.

135 cytic cells, including the beta(2) integrin, complement receptor 3 (CR3).

136 ed a phagocytic marker, via interaction with complement receptor 3 (CR3).

137 orming RTX cytolysin (Hly) moiety, binds the complement receptor 3 (CR3, alpha(M)beta(2), CD11b/CD18,

138 rior studies indicated the ability of Abs to complement receptor 3 (CR3, CD11b/CD18) to suppress the

139 D209), Dectin-1, Toll-like receptors (TLRs), complement receptor 3 (CR3, CD11b/CD18), nucleotide olig

140 C. albicans mediated by the beta2 integrin, complement receptor 3 (CR3, CD11b/CD18, alphaMbeta2).

141 hers HPCs via the inserted (I) domain of HPC complement receptor 3 (CR3, CD11b/CD18, Mac-1).

142 Complement receptor 3 (CR3; also called CD11b/CD18), a b

143 the fimbriae of P. gingivalis interact with complement receptor 3 (CR3; CD11b/CD18) in monocytes/mac

144 been shown to function via the iC3b-receptor complement receptor 3 (CR3; CD11b/CD18) thereby enhancin

145 KO of complement receptor 3 (CR3; Itgam), which is only expres

146 neutrophil opsonic receptors, FcgammaRs and complement receptor 3 (Mac-1) to cellular cytotoxic resp

147 We have shown previously that complement receptor 3 and Akt kinase play important role

148 roglial phagocytosis stimulated by fAbeta or complement receptor 3 and argue that this may, in part,

149 modulation of TLR8 signaling was mediated by complement receptor 3 and led to enhanced infection.

150 roduce a new picture of Fcgamma receptor and complement receptor 3 intracellular signaling have been

151 ae allowed P. gingivalis to exploit the TLR2/complement receptor 3 pathway for intracellular entry, i

152 oglia-specific phagocytic signaling pathway, complement receptor 3(CR3)/C3.

153 alpha(M)beta(2) integrin (complement receptor 3) is a major receptor for phagocyto

154 ITGAM encodes the integrin CD11b, a part of complement receptor 3, a novel candidate gene implicated

155 ly, attributable to failure to interact with complement receptor 3, although not with TLR2.

156 egrin (CD11b/CD18), macrophage-1 antigen, or complement receptor 3, as a cellular receptor for leukoc

157 lex with its receptor (the alpha-I domain of complement receptor 3, CD11b-I), both for the human and

158 ound to depend on beta-glucan recognition by complement receptor 3, require Fn and ERK but not ROS, a

159 MN with C5a led to upregulation of activated complement receptor 3, resulting in enhanced complement

160 complement receptor 3, resulting in enhanced complement receptor 3-dependent PMN-ADCC against tumor c

161 mma receptor internalization pathway but not complement receptor 3-dependent uptake, which is control

162 CyaA penetrates the complement receptor 3-expressing phagocytes and ablates

163 CyaA penetrates complement receptor 3-expressing phagocytes and catalyze

164 Furthermore, overexpressing stathmin reduces complement receptor 3-mediated phagocytosis and cellular

165 o inhibited by blocking Abs directed against complement receptor 3.

166 l fractalkine (also known as CXCL1), but not complement receptor 3.

167 1 in macrophages that lack mannose receptor, complement receptors 3 and 4, type A scavenger receptor,

168 g, attributed to diminished AM expression of complement receptor-3 (CR3), which is exploited by P. gi

169 e desialylated neurites was mediated via the complement receptor-3 (CR3; CD11b/CD18).

170 CD11c/CD18 (alphaXbeta2, p150/95, or complement receptor 4, CR4) is a monocyte/macrophage-enr

171 colonization is associated with a variant of complement receptor 5a, the cellular target of the lukS

172 s integrin-mediated phagocytosis through the complement receptor alpha(M)beta(2).

173 coexpressed with CD18 to form the Mac-1/CR3 complement receptor and adhesion molecule.

174 Using a fusion protein of a complement receptor and an IgG Fc fragment, therapeutic

175 3bBb).C3) interferes with the interaction of complement receptors and C3b.

176 possible effects of ANE on the expression of complement receptors and Fc receptors were examined usin

177 activation did not promote infection through complement receptors and inhibited anti-H IgG-mediated e

178 is by macrophages is strongly dependent upon complement receptors and upon serum with intact compleme

179 entiates among the contributions from Fc and complement receptors, and provides a tool for estimating

180 receptors and in conditions of FcgammaR and complement receptor blockage with specific Abs.

181 in 8 (aqp8), adrenomedullin receptor (admr), complement receptor C1qR-like (crl), scavenger receptor

182 All measures were reversed by blocking C3a complement receptor (C3aR), alternative complement pathw

183 ional roles for both C5a receptors, that is, complement receptor C5a (C5aR) and C5a receptor-like 2 (

184 Mice deficient in complement receptor C5a did not show increased MMP-9 act

185 Since the complement receptor C5a receptor-like 2 (C5L2) is expres

186 d an intimate crosstalk between TLR2 and the complement receptor C5aR and can contribute to the persi

187 Crosstalk between the complement receptor C5aR and FcgammaRIIa on neutrophils

188 deficient in complement factor 5 (C5) or the complement receptor C5aR mounted robust IL-17A responses

189 Engagement of the complement receptor C5aR on neutrophils induces expressi

190 nase 3 and subsequent down-regulation of the complement receptor C5aR.

191 CXCR2 and CCR2 as targets for HlgAB, and the complement receptors C5aR and C5L2 as targets for HlgCB.

192 However, the distinct roles of the two complement receptors C5aR1 and C5aR2 in bone has to date

193 uman phagocytes through interaction with the complement receptors C5aR1 and C5aR2.

194 brane movement impedes the clustering of the complement receptor CD11b/CD18 on PMNs and, in turn, dec

195 the viral envelope glycoprotein gp350 to the complement receptor CD21.

196 radiation bone marrow-chimeric mice lacking complement receptors CD21 and CD35 on stromal cells elic

197 Mice lacking complement receptors CD21/35 partially resist terminal p

198 ts function in B cell activation through the complement receptors CD21/35.

199 In addition, complement receptors (CD21 and CD35) on B cells cooperat

200 binding of complement-tagged antigens to the complement receptor, CD21, and to the BCR.

201 human T cells, autocrine stimulation of the complement receptor CD46, and specifically its intracell

202 This study found that human complement receptor (CR) 4 selectively bound fibrillar a

203 Follicular dendritic cells (FDCs) and complement receptor (Cr)1 and complement receptor (Cr)2

204 lls (FDCs) and complement receptor (Cr)1 and complement receptor (Cr)2 are important for the generati

205 Notably, blocking complement receptor (CR)3 significantly reduced Aspergil

206 complement-decorated pathogens with various complement receptors (CR) on phagocytes.

207 Complement and complement receptors (CR) play a central role in immune

208 Complement receptors (CR), CR3 (CD11b), and CR4 (CD11c)

209 terium kansasii enter macrophages, using the complement receptors CR1, CR3, CR4, and the mannose rece

210 Our new results suggest that complement receptors CR1/2, CR3, and CR4 all play import

211 n, but not murine, erythrocytes also present complement receptor (CR1), which binds Ad5 in the presen

212 NE significantly inhibited the production of complement receptors (CR1, CR3, and CR4) and Fc receptor

213 to replace endogenous murine Cr2 with human complement receptors, CR1 and CR2 (B6.CR2CR1).

214 otypes resulted from polymorphisms in the C3 complement receptor Cr2 gene.

215 ulating humoral immunity largely through the complement receptor CR2, which forms a coreceptor on B c

216 hagocytosis, altered the distribution of the complement receptor CR3 (CD11b/CD18), enhanced the intra

217 The complement receptor CR3 (CD11b/CD18, Mac-1) mediates the

218 Inhibition of C1q, C3, or the microglial complement receptor CR3 reduces the number of phagocytic

219 cteria from the mannose receptor (MR) to the complement receptor CR3, the scavenger receptor A (SRA),

220 Host immune cells use type 3 complement receptors (CR3) to regulate excess TNF-alpha

221 Complement C3 but not C5, and complement receptor CRIg but not CR3, are involved in ca

222 ing or gene ablation of the newly identified complement receptor CRIg, but not complement receptor 3

223 Complement receptors (CRs) CD21 and CD35 form a corecept

224 the individual roles of the alphavbeta5 and complement receptors (CRs) in the phagocytosis and induc

225 Complement receptors (CRs), expressed notably on myeloid

226 B cells captured immune complexes by a complement receptor-dependent mechanism from macrophage

227 CRIg, a complement receptor expressed on macrophages, binds to C

228 ly, deficiency of CRIg, CR3, and other known complement receptors failed to prevent Crry-deficient er

229 y result from reduction of the expression of complement receptors, Fc receptors, and F-actin formatio

230 Expression of complement receptors, Fc receptors, and F-actin in ANE-t

231 gC1qR, a complement receptor for C1q, plays a pivotal role in the

232 Integrin alpha(X)beta(2) functions as complement receptor for iC3b and mediates recognition an

233 hages (M/M(Phi)s) through interaction with a complement receptor gC1qR.

234 The complement receptor Ig (CRIg) is selectively expressed b

235 The CD21/35 proteins are complement receptors implicated in controlling and inter

236 tosis involves ingestion through both Fc and complement receptors in the absence of complement.

237 reactive antibodies, we examined the role of complement receptors in the production of alphaGal-speci

238 They express various complement receptors, including those for C3a and C5a.

239 ocytic index was caused by interference with complement receptor ingestion as a consequence of satura

240 t role in clearing particles in circulation, complement receptors involved in this process have yet t

241 m, via inhibition of Toll-like receptor- and complement receptor-mediated activation.

242 , we examined the role of SP-A in modulating complement receptor-mediated phagocytosis.

243 ved MPhi, we now identify CD11b as the major complement receptor mediating MPhi adherence to the larv

244 These mechanisms are mediated by the complement receptor of immunoglobulin family (CRIg).

245 e was recently independently identified as a complement receptor of the Ig superfamily (CRIg) and was

246 a targeted complement inhibitor, comprising complement receptor of the Ig superfamily (CRIg) fused w

247 A complement receptor of the Ig superfamily (CRIg) is expr

248 rophages characterized by high expression of complement receptor of the Ig superfamily (CRIg), a rece

249 SPECT/muCT) imaging using Nanobodies against complement receptor of the Ig superfamily (CRIg), found

250 lated with disease protection, including the complement receptor of the immunoglobulin superfamily (C

251 Previously, we have shown that human complement receptor of the immunoglobulin superfamily (C

252 the identification and characterization of a Complement Receptor of the Immunoglobulin superfamily, C

253 pture of bacteria-platelet-complexes via the complement receptor of the immunoglobulin superfamily, C

254 tulated that surface-bound C3 interacts with complement receptors on alloreactive T cells or on antig

255 nsported into B cell follicles by binding to complement receptors on B cells.

256 We evaluated the expression of several complement receptors on cDCs and confirmed that cDCs tha

257 otein, resulting in enhanced phagocytosis by complement receptors on human alveolar macrophages.

258 that culminates in the activation of surface complement receptors on immune cells.

259 lement complex and lowered the expression of complement receptors on monocytes in whole blood in resp

260 platelets and erythrocytes engage different complement receptors on tissue macrophages in vivo.

261 on the particle surface serve as targets for complement receptors present on phagocytic cells.

262 ansplant (day 2) together with inhibition of complement receptors prevents engraftment syndrome and a

263 tic index but increased phagocytosis through complement receptors rapidly compensated for this effect

264 ment and neurodegeneration, we asked whether complement receptors regulate neurogenesis.

265 eal injection of cobra venom factor (CVF) or complement receptor-related gene y (Crry)-Ig, a potent C

266 nhibition of C3 by overexpression of soluble complement receptor-related protein y in an AD mouse mod

267 hanism and the possible involvement of other complement receptors remain unclear.

268 However, blocking Fc and complement receptors resulted in a major diminution of c

269 igated whether App1 would also bind to other complement receptor(s), we found that App1 does bind to

270 zing complement regulator derived from human complement receptor type 1 (APT070) and then subjected t

271 (tPA) to a monoclonal antibody (mAb) against complement receptor type 1 (CR1) expressed primarily on

272 Complement receptor type 1 (CR1) is a membrane receptor

273 Human complement receptor type 1 (CR1, CD35) is a type I membr

274 4) on the merozoite surface interacting with complement receptor type 1 (CR1, CD35) on the erythrocyt

275 The extracellular domain of the complement receptor type 1 (CR1; CD35) consists entirely

276 ndertaken to determine whether soluble human complement receptor type 1 (TP10), a potent inhibitor of

277 resence of a cofactor such as factor H (fH), complement receptor type 1, membrane cofactor protein, o

278 Human complement receptor type 2 (CR2 and CD21) is a cell memb

279 The interactions between the complement receptor type 2 (CR2) and the C3 complement f

280 complement regulator (SCR) domains, whereas complement receptor type 2 (CR2) has 15 SCR domains and

281 the Epstein-Barr virus glycoprotein gp350 by complement receptor type 2 (CR2) is critical for viral a

282 short complement regulator (SCR) domains of complement receptor type 2 (CR2) that bind to complement

283 protein containing the C3d-binding region of complement receptor type 2 (CR2) was then conjugated to

284 Complement receptor type 2 (CR2)/CD21 plays a key role i

285 irst two short consensus repeats (SCR1-2) of complement receptor type 2 (CR2, CD21) and C3d in soluti

286 Complement receptor type 2 (CR2, CD21) forms a tight com

287 Complement receptor type 2 (CR2, CD21) is a cell surface

288 Complement receptor type 2 (CR2, CD21) is a cell surface

289 therapeutic fusion protein linking the human complement receptor type 2 (CR2/CD21) C3 fragment (C3fra

290 Human complement receptor type 2 (CR2/CD21) is a B lymphocyte

291 Complement receptor type 2 (CR2/CD21) is essential for t

292 Complement receptor type 2 (CR2/CD21), in association wi

293 d and inactivated C3b, which are ligands for complement receptor type 2 (CR2/CD21), the aim of the cu

294 C3dg adducts of Ag can coligate complement receptor type 2 (CR2; CD21) and the B cell Ag

295 ar the CD11b/CD18 beta2 integrin heterodimer complement receptor type 3/Mac-1.

296 with an alphaI domain, alpha(X)beta(2), the complement receptor type 4.

297 (MCP), decay accelerating factor (DAF), and complement receptors type 1 (CR1) and 2 (CR2).

298 e the antibody response in mice deficient in complement receptor types 1 and 2 (CR1 and CR2) has rais

299 To further characterize complement and complement receptors, we have identified a role for C3 i

300 ant part of the innate immune system, namely complement receptors, with the central molecular mechani